Home Search
sopa - search results
If you're not happy with the results, please do another search
Initiating Coverage on Society Pass (SOPA).
Institutional Analyst: Society Pass (Nasdaq: SOPA) - Acquiring and Incubating Startups in the Heart of the Asian Silicon Valley
Society Pass (SOPA) Research Reports
RESEARCH REPORT ARCHIVE
December 27th, 2023. Litchfield Hills Research - $4.00 Price Target.
Adding Society Pass (SOPA) $0.96 to the Watch List
Amazing Fast Grower, in the Asian Silicon Valley.
After a wildly successful IPO debut and subsequent tumble, Society...
Digital Coaches at Dario (DRIO) Significantly Reduce Depression.
63% of Users Show Significant Improvement After Impact of Digital Coaching and Breathing Exercises as Part of the Dario Health Platform.
Plansource Invites DarioHealth (DRIO) Into 50 Broker Partnership Network, Serving 5 Million Patients.
This looks like a coup for DarioHealth (DRIO), getting it's digital health solutions in front of more than 5 million new potential...
Adding Dario Health (DRIO) $2.81 to Watch List.
LIVE QUOTE
Adding DarioHealth to Top Stocks of 2023...
Our 10 Top Turnaround Situations Under $5.00.
Can These Stocks Double in Value, and Still be 70% off Their Recent High?
Read More...
Asia-Pacific: A Region of Stability Amidst Economic Uncertainty
Contrary to the Western markets, there is a growing consensus that the Asia Pacific is emerging as a relatively safe harbour in...
Report: Expedia, Doordash, eCommerce Fashion Retailer and YouTube All Rolled Into One?
Society Pass (SOPA) has Acquired and is Operating in Six Verticals, With More to Come.
Society Pass currently has...
Three That Doubled, Three More That May Double.
Ardelyx $3.00 (ARDX) Gains 117%, Provention Bio $8.75 (PRVB) Gains 134%, and PharmaTher (PHRRF) up 154%. Blue Skies Ahead - For All...
Latest article
Institutional Analyst Newsletter. Citius (CTXR), GeoVax (GOVX.
DERBY WEEKEND - WE'RE HEADED TO TAMPA!HAT'S ON, DRINK'S UPADDING CITIUS PHARMA (CTXR) $0.66, TO WATCHLISTUPDATING GEOVAX LABS (GOVX) $1.43OUR $26...
Adding Citius Pharma (CTXR) $0.66 to 2024 Watch List.
Three Years Since we Last Added Citius (CTXR) to the Watch List, and it Looks Better Than Ever!
Citius Pharmaceuticals (CTXR) Prospectus, Powerpoint & Fact Sheet.
CRANFORD, N.J., April 26, 2024 /PRNewswire/ -- Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius" or the "Company"), a late-stage biopharmaceutical company dedicated to the development and commercialization...
